随着时间的推移,发作频率趋势在治疗耐药的焦点中
Ojas Potnis1, Gabriel Biondo2, Rachel Sukonik3
1Department of Neurology, NYU Langone Health, New York, New York.
JAMA neurology
|October 20, 2025
概括
焦点治疗耐药性 (FTRE) 可能会随着时间的推移而改善,抗发作药物 (ASM) 的添加有助于减少发作,但很少实现自由. 在这项研究中,使用设备并没有改变发作轨迹.
科学领域:
- 神经学 神经学
- 发病学 (Epileptology) 是一个专业的学科.
- 临床试验 临床试验
背景情况:
- 开放标签研究表明抗发作药物 (ASM) 和设备可能会改变焦点治疗耐药性 (FTRE) 的疾病.
- 了解FTRE的趋势对于评估治疗反应和潜在的疾病修饰效应至关重要.
研究的目的:
- 在18至36个月的随访期内调查FTRE患者的发作频率趋势.
- 评估包括ASM和设备在内的干预措施对FTRE发作减少的影响.
主要方法:
- 展望性,观察性,多中心研究 (人类项目2) 涉及146名FTRE患者.
- 通过电子日记,检查和医疗记录收集的数据,跟踪发作频率,药物和设备使用.
- 分析的重点是扣押自由率和频率减少,比较干预效应.
主要成果:
- 在研究的下半年,68.3%的参与者减少了发作的频率,平均每月减少68.73%.
- 在66.7%的病例中,添加ASM导致了发作频率的减少,但发作不常见.
- 使用植入式设备的参与者与没有设备的参与者相比,显示出类似的发作减少轨迹.
结论:
- 随着时间的推移,FTRE可能会表现出改善,而不依赖于具体的干预措施.
- 虽然ASM有助于减少发作,但它们在FTRE中实现完全无发作的可能性很低.
- 这些发现需要谨慎解释关于FTRE疾病修饰作用的开放标签研究,并强调需要进一步研究.
相关概念视频
Epilepsy and Seizures: Overview
1.1K
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.1K
Seizures: Classification
1.3K
Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
1.3K
Antiepileptic Drugs: Sodium Channel Blockers
1.5K
Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
1.5K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
785
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
785
Antiepileptic Drugs: Potassium Channel Activators
586
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
586
Electroconvulsive Therapy
771
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
771


